Published in Am J Gastroenterol on October 01, 2002
Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium | NCT01783314
Development of a Breath Test for Monitoring Patients With Liver Disease | NCT00244569
Prospective Comparison Between TE, SWE and MRE (FULLFIBRO01) (FULLFIBRO01) | NCT03293953
Liver fibrosis. J Clin Invest (2005) 17.27
Liver cirrhosis. Lancet (2008) 6.11
Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut (2005) 5.20
Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06
Quantifying hepatic shear modulus in vivo using acoustic radiation force. Ultrasound Med Biol (2008) 4.37
Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol (2010) 3.30
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology (2010) 2.68
Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling. J Magn Reson Imaging (2009) 2.41
Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging (2013) 2.22
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol (2004) 2.19
KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol (2012) 2.10
Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging (2010) 1.96
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88
Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis (2009) 1.80
Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology (2013) 1.77
Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol (2006) 1.63
The precarious state of the liver after a Fontan operation: summary of a multidisciplinary symposium. Pediatr Cardiol (2012) 1.62
Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. J Biomed Sci (2010) 1.62
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol (2005) 1.54
Quantification of liver fat with magnetic resonance imaging. Magn Reson Imaging Clin N Am (2010) 1.51
Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C. J Clin Gastroenterol (2014) 1.44
An Increased Ratio of Glycated Albumin to HbA1c Is Associated with the Degree of Liver Fibrosis in Hepatitis B Virus-Positive Patients. Gastroenterol Res Pract (2014) 1.42
Advanced MRI methods for assessment of chronic liver disease. AJR Am J Roentgenol (2009) 1.39
Use of administrative claims data for identifying patients with cirrhosis. J Clin Gastroenterol (2013) 1.39
Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis (2008) 1.39
Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology (2013) 1.35
Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol (2007) 1.34
Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol (2011) 1.34
Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One (2012) 1.24
Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol (2014) 1.22
Separation of advanced from mild hepatic fibrosis by quantification of the hepatobiliary uptake of Gd-EOB-DTPA. Eur Radiol (2012) 1.22
Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis C. J Clin Pathol (2006) 1.21
Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis. AIDS (2012) 1.21
Patient preference and willingness to pay for transient elastography versus liver biopsy: A perspective from British Columbia. Can J Gastroenterol Hepatol (2015) 1.19
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology (2009) 1.18
Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors. J Gastroenterol (2007) 1.17
A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. PLoS One (2011) 1.16
Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int (2011) 1.15
Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol (2009) 1.15
Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. Eur Radiol (2013) 1.15
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
Percutaneous liver biopsy practice patterns among Canadian hepatologists. Can J Gastroenterol (2013) 1.15
Test-retest repeatability of MR elastography for noninvasive liver fibrosis assessment in hepatitis C. J Magn Reson Imaging (2011) 1.14
RDW to platelet ratio: a novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B. PLoS One (2013) 1.14
Accuracy of MR elastography and anatomic MR imaging features in the diagnosis of severe hepatic fibrosis and cirrhosis. J Magn Reson Imaging (2012) 1.13
Liver stiffness: a novel parameter for the diagnosis of liver disease. Hepat Med (2010) 1.13
A comparative study of non-invasive methods for fibrosis assessment in chronic HCV infection. Hepat Mon (2010) 1.13
Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. J Transl Med (2007) 1.13
Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol (2013) 1.12
Review of MR elastography applications and recent developments. J Magn Reson Imaging (2012) 1.12
Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. Hepatology (2012) 1.12
Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. World J Gastroenterol (2010) 1.12
SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients. Proteomics (2012) 1.11
Acoustic Radiation Force Impulse (ARFI) and Transient Elastography (TE) for evaluation of liver fibrosis in HIV-HCV co-infected patients. BMC Infect Dis (2014) 1.11
Head-to-head comparison of transient elastography (TE), real-time tissue elastography (RTE), and acoustic radiation force impulse (ARFI) imaging in the diagnosis of liver fibrosis. J Gastroenterol (2012) 1.10
Automated liver stiffness measurements with magnetic resonance elastography. J Magn Reson Imaging (2012) 1.10
A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. PLoS One (2012) 1.10
GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteomics (2009) 1.09
Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol (2008) 1.08
Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med (2007) 1.07
Clinical applications of transient elastography. Clin Mol Hepatol (2012) 1.07
Non-invasive assessment of liver fibrosis. Ann Gastroenterol (2012) 1.07
MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. J Hepatol (2016) 1.06
Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology (2012) 1.06
Evaluation of acoustic radiation force impulse imaging for determination of liver stiffness using transient elastography as a reference. World J Gastroenterol (2012) 1.05
MR elastography of liver fibrosis: preliminary results comparing spin-echo and echo-planar imaging. Eur Radiol (2008) 1.05
Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol (2014) 1.05
Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients. Hepat Mon (2012) 1.05
New method for assessing liver fibrosis based on acoustic radiation force impulse: a special reference to the difference between right and left liver. J Gastroenterol (2011) 1.05
Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives. World J Gastroenterol (2013) 1.02
Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. World J Gastroenterol (2009) 1.02
A comparison of hepatopathologists' and community pathologists' review of liver biopsy specimens from patients with hepatitis C. Clin Gastroenterol Hepatol (2008) 1.02
Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology (2014) 1.02
The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection. PLoS One (2011) 1.02
Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. Can J Gastroenterol (2010) 1.02
Assessing liver fibrosis with serum marker models. Clin Biochem Rev (2007) 1.02
Pediatric nonalcoholic fatty liver disease: A clinical and laboratory challenge. World J Hepatol (2010) 1.01
Non invasive tools for the diagnosis of liver cirrhosis. World J Gastroenterol (2014) 1.00
Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol (2014) 1.00
Clinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels. Hepat Mon (2012) 0.99
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99
The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study. BMC Gastroenterol (2005) 0.99
Usefulness of noninvasive transient elastography for assessment of liver fibrosis stage in chronic hepatitis C. World J Gastroenterol (2006) 0.98
Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci (2003) 0.97
Aspartate aminotransferase to platelet ratio index correlates with hepatic cirrhosis but not with fibrosis in pediatric patients with intestinal failure. J Pediatr Gastroenterol Nutr (2013) 0.97
Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. J Gastroenterol (2013) 0.96
Assessment of Liver Stiffness in Pediatric Fontan Patients Using Transient Elastography. Can J Gastroenterol Hepatol (2016) 0.96
Evaluation of liver fibrosis by transient elastography using acoustic radiation force impulse: comparison with Fibroscan(®). J Gastroenterol (2011) 0.96
Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis. Eur Radiol (2010) 0.96
Hepatic MR Elastography: Clinical Performance in a Series of 1377 Consecutive Examinations. Radiology (2015) 0.95
Reduction of liver stiffness by antiviral therapy in chronic hepatitis B. J Gastroenterol (2011) 0.95
Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. J Gastroenterol (2009) 0.94
Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2012) 0.94
Liver biopsy for histological assessment: The case against. Saudi J Gastroenterol (2010) 0.94
Transient elastography for predicting esophageal/gastric varices in children with biliary atresia. BMC Gastroenterol (2011) 0.94
The feasibility and reliability of transient elastography using Fibroscan®: a practice audit of 2335 examinations. Can J Gastroenterol Hepatol (2014) 0.94
The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy. PLoS One (2014) 0.93
Shear-wave elastography for the estimation of liver fibrosis in chronic liver disease: determining accuracy and ideal site for measurement. Radiology (2014) 0.93
Is ARFI elastography reliable for predicting fibrosis severity in chronic HCV hepatitis? World J Radiol (2011) 0.93
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 4.33
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med (2009) 4.21
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Histological outcome during long-term lamivudine therapy. Gastroenterology (2003) 3.88
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med (2009) 3.41
Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int (2011) 3.36
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat (2002) 2.43
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 2.28
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology (2004) 2.17
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95
Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol (2005) 1.94
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl (2005) 1.87
The North American Study for the Treatment of Refractory Ascites. Gastroenterology (2003) 1.87
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding: a randomized trial. Gastroenterology (2006) 1.82
Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. Am J Clin Pathol (2008) 1.79
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology (2010) 1.79
Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf (2011) 1.76
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology (2005) 1.76
Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology (2012) 1.74
Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl (2006) 1.72
Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl (2008) 1.72
Determinants of recurrence after sigmoid resection for uncomplicated diverticulitis. Dis Colon Rectum (2003) 1.70
Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol (2004) 1.68
Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl (2009) 1.67
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med (2014) 1.64
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol (2011) 1.61
Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl (2007) 1.61
Testosterone and 17β-estradiol have opposite effects on podocyte apoptosis that precedes glomerulosclerosis in female estrogen receptor knockout mice. Kidney Int (2010) 1.60
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology (2002) 1.60
Spontaneous clearance of hepatitis C virus after liver transplantation in two patients coinfected with hepatitis C virus and human immunodeficiency virus. Liver Transpl (2008) 1.59
Transplantation: impact of pretransplant renal insufficiency. Liver Transpl (2008) 1.58
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int (2008) 1.56
Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis. Liver Transpl (2013) 1.52
Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology (2006) 1.50
Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci (2007) 1.50
Large vessel involvement in ANCA-associated vasculitides: report of a case and review of the literature. Clin Rheumatol (2004) 1.50
Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol (2007) 1.49
Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology (2004) 1.49
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol (2004) 1.47
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol (2002) 1.43
Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2009) 1.41
Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology (2007) 1.38
Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era. Liver Transpl (2011) 1.37
Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol (2009) 1.37
Acetaminophen safety and hepatotoxicity--where do we go from here? Expert Opin Drug Saf (2007) 1.36
New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology (2013) 1.35
Alcohol and hepatitis C. Semin Liver Dis (2004) 1.34
Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis (2008) 1.33
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology (2004) 1.30
Serum apoptosis markers in acute liver failure: a pilot study. Clin Gastroenterol Hepatol (2007) 1.29
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology (2007) 1.27
Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol (2008) 1.26
US-guided core-needle biopsy of the breast: how many specimens are necessary? Radiology (2003) 1.24
Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf (2013) 1.23
Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol (2006) 1.21
Allograft survival following adult-to-adult living donor liver transplantation. Am J Transplant (2004) 1.20
Portal vein thrombosis: a concise review. Am J Gastroenterol (2002) 1.20
Current trends in living donor liver transplantation for primary sclerosing cholangitis. Transplantation (2011) 1.19
Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci (2012) 1.18
The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease. Hepatology (2014) 1.17
Resistance to glomerulosclerosis in B6 mice disappears after menopause. Am J Pathol (2003) 1.17
Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology (2014) 1.16
Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology (2005) 1.15
Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. Am J Pathol (2003) 1.12
The current economic burden of cirrhosis. Gastroenterol Hepatol (N Y) (2011) 1.11
Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc (2010) 1.06
Outcomes after liver transplantation: chronic kidney disease. Liver Transpl (2009) 1.05
Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs (2013) 1.05
T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatology (2005) 1.04
Laparoscopic resection of rectal cancer results in higher lymph node yield and better short-term outcomes than open surgery: a large single-center comparative study. Dis Colon Rectum (2013) 1.03
Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol (2007) 1.03